1. NF-κB Anti-infection Metabolic Enzyme/Protease
  2. NF-κB Bacterial HIV Endogenous Metabolite
  3. Maslinic acid

Maslinic acid  (Synonyms: Crategolic acid; 2α-Hydroxyoleanolic acid)

Cat. No.: HY-N0629 Purity: 99.87%
Handling Instructions Technical Support

Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

For research use only. We do not sell to patients.

CAS No. : 4373-41-5

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

Other Forms of Maslinic acid:

Top Publications Citing Use of Products

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Jan 19:158:110120.  [Abstract]

    Maslinic acid (MA, 80 mg/L; 100 μL; i.p.) efficiently suppressed the transcription of Msp65. The mRNA levels of Msp65 were analyzed in the liver and spleen using qRT-PCR at different time points (6, 12, 24, 36, 48, 60 and 72 h post injection) after intraperitoneal injection with 80 mg/L MA.

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Jan 19:158:110120.  [Abstract]

    Survival curves of largemouth bass injected with different doses of Maslinic acid (MA, 5-640 mg/L; 100 μL; i.p.).

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Jan 19:158:110120.  [Abstract]

    Histological morphologies in the liver and spleen under Maslinic acid (MA, 80 mg/L; 100 μL; i.p.) treatment. Histological analysis revealed no pathological changes in the liver and spleen tissues of largemouth bass treated with 80 mg/L MA. Scale bars represented 50 μm.

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2022 Jun;45(3):367-379.  [Abstract]

    WB analysis of phosphorylated and total NF-κB in IRAK2OE cells treated with 20 µM Maslinic acid (MA) for different times (0, 1, 2, 6, 12 and 24 h). Phosphorylated NF-κB was estimated by normalizing the band intensity of p-NF-κB against that of total NF-κB. The ratios below indicate the relative activity of treated cells compared with that of untreated cells from three independent experiments. The results showed that the level of phosphorylated NF-κB decreased in a time-dependent manner after treatment with MA.

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Mar 1:500:228-243.

    Western blot analysis of GemR DT6066/MiaPaca2 cells treated with Maslinic acid (20 μM; 12 h) (NF-κB inhibitor) or placebo. The results showed that depletion of p65 by an inhibitor, Maslinic acid, significantly reduced p65 phosphorylation and its downstream B4GALT1 expression at protein levels in both mouse and human gemcitabine-resistant cells.

    Maslinic acid purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Mar 1:500:228-243.

    RT-PCR analysis of B4GALT1 mRNA expression in the GemR DT6066/MiaPaca2 cells treated with Maslinic acid (20 μM; 12 h) (NF-κB inhibitor) or placebo. The results showed that depletion of p65 by an inhibitor, Maslinic acid, significantly downregulated B4GALT1 expression at mRNA levels in both mouse and human gemcitabine-resistant cells.

    View All NF-κB Isoform Specific Products:

    View All HIV Isoform Specific Products:

    View All Endogenous Metabolite Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

    IC50 & Target[1]

    p65

     

    Cellular Effect
    Cell Line Type Value Description References
    518A2 EC50
    13.7 μM
    Compound: 3; MA
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    518A2 EC50
    13.7 μM
    Compound: 6
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    518A2 EC50
    13.7 μM
    Compound: MA
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    518A2 EC50
    13.7 μM
    Compound: MA
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    518A2 EC50
    13.7 μM
    Compound: MA
    Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    518A2 IC50
    13.7 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    518A2 IC50
    13.7 μM
    Compound: MA
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    518A2 IC50
    13.7 μM
    Compound: MA
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 24440377]
    8505C EC50
    17 μM
    Compound: 6
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 28033541]
    8505C EC50
    17 μM
    Compound: MA
    Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    8505C EC50
    17 μM
    Compound: MA
    Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    8505C IC50
    17 μM
    Compound: 1
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 24161703]
    8505C IC50
    17 μM
    Compound: MA
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 24361521]
    8505C IC50
    17 μM
    Compound: MA
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 24440377]
    A2780 EC50
    19.5 μM
    Compound: 3; MA
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A2780 EC50
    19.5 μM
    Compound: 6
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A2780 EC50
    19.5 μM
    Compound: MA
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    A2780 EC50
    19.5 μM
    Compound: MA
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    A2780 EC50
    19.5 μM
    Compound: MA
    Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    A2780 IC50
    19.5 μM
    Compound: 1
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    A2780 IC50
    19.5 μM
    Compound: MA
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    A2780 IC50
    19.5 μM
    Compound: MA
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 24440377]
    A549 EC50
    23.4 μM
    Compound: 3; MA
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A549 EC50
    23.4 μM
    Compound: 6
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A549 EC50
    23.4 μM
    Compound: MA
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    A549 EC50
    23.4 μM
    Compound: MA
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    A549 EC50
    23.4 μM
    Compound: MA
    Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    A549 IC50
    23.4 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    A549 IC50
    23.4 μM
    Compound: MA
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    A549 IC50
    23.4 μM
    Compound: MA
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 24440377]
    B16-F10 IC50
    36.2 μM
    Compound: 2, MA, Maslinic acid
    Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
    [PMID: 24480359]
    B16-F10 IC50
    36.2 μM
    Compound: II, Maslinic acid
    Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
    Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    B16-F10 IC50
    36.2 μM
    Compound: II; MA; Maslinic acid
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    B16-F10 IC50
    36.2 μM
    Compound: MA
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    B16-F10 IC50
    > 10 μM
    Compound: I; MA
    Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 33956447]
    BV-2 IC50
    17.8 μM
    Compound: 5
    Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
    Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
    [PMID: 28358502]
    FaDu EC50
    17 μM
    Compound: MA
    Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    HSC-T6 EC50
    17.3 nM
    Compound: 205
    Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
    [PMID: 29353722]
    HT-29 EC50
    28.8 μM
    Compound: 3; MA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    HT-29 EC50
    28.8 μM
    Compound: 6
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    HT-29 EC50
    28.8 μM
    Compound: MA
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    HT-29 EC50
    28.8 μM
    Compound: MA
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    HT-29 EC50
    28.8 μM
    Compound: MA
    Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    HT-29 IC50
    28.8 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    HT-29 IC50
    28.8 μM
    Compound: MA
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    HT-29 IC50
    28.8 μM
    Compound: MA
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 24440377]
    HT-29 IC50
    32.2 μM
    Compound: II, Maslinic acid
    Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
    Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    HT-29 IC50
    32.2 μM
    Compound: II; MA; Maslinic acid
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    HT-29 IC50
    32.2 μM
    Compound: MA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    HT-29 IC50
    > 10 μM
    Compound: I; MA
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 33956447]
    HepG2 IC50
    99.2 μM
    Compound: II, Maslinic acid
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    HepG2 IC50
    99.2 μM
    Compound: II; MA; Maslinic acid
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    HepG2 IC50
    99.2 μM
    Compound: MA
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    HepG2 IC50
    > 10 μM
    Compound: 17
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    HepG2 IC50
    > 10 μM
    Compound: I; MA
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 33956447]
    HepG2 IC50
    > 100 μM
    Compound: 12
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    KB ED50
    51.5 μM
    Compound: 5
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    [PMID: 16562832]
    KB IC50
    > 100 μM
    Compound: 12
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    Lu1 IC50
    > 100 μM
    Compound: 12
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    MCF7 EC50
    24.4 μM
    Compound: MA
    Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
    Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    MCF7 EC50
    37.2 μM
    Compound: 3; MA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    MCF7 EC50
    37.2 μM
    Compound: MA
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    MCF7 EC50
    > 30 μM
    Compound: 6
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    MCF7 EC50
    > 30 μM
    Compound: MA
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    MCF7 IC50
    16.6 μM
    Compound: MA
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    MCF7 IC50
    24.4 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    MCF7 IC50
    > 10 μM
    Compound: 17
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    MCF7 IC50
    > 100 μM
    Compound: 12
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    MDCK CC50
    23.3 μM
    Compound: Maslinic acid
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs
    Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs
    [PMID: 29394063]
    NCI-N87 IC50
    > 10 μM
    Compound: 17
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    NIH3T3 EC50
    16.6 μM
    Compound: MA
    Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
    [PMID: 31330447]
    NIH3T3 EC50
    21.1 μM
    Compound: 3; MA
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    NIH3T3 EC50
    21.1 μM
    Compound: 6
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    NIH3T3 EC50
    21.1 μM
    Compound: MA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    NIH3T3 EC50
    21.1 μM
    Compound: MA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    NIH3T3 IC50
    16.6 μM
    Compound: 1
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 24161703]
    NIH3T3 IC50
    16.6 μM
    Compound: MA
    Cytotoxic activity against mouse NIH/3T3 cells by SRB assay
    Cytotoxic activity against mouse NIH/3T3 cells by SRB assay
    [PMID: 26383128]
    NIH3T3 IC50
    21.1 μM
    Compound: MA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 24440377]
    NIH3T3 IC50
    21.4 μM
    Compound: MA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    Sf21 IC50
    > 40 μM
    Compound: 11
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    [PMID: 31774676]
    In Vitro

    Maslinic acid (MA) inhibits LPS-induced NF-κB translocation to nucleus and phosphorylation of IκB-α. Maslinic acid has also been reported to suppress NF-κB regulated osteoclastogenesis in bone marrow monocytes and inhibit TNF-α-induced NF-κB activity and its downstream genes’ expression in pancreatic cancer cells. To confirm if the anti-inflammatory effects of olive pomace extracts (OPEs) inRAW264.7 cells can be attributed to Maslinic acid, dose-dependence experiments determined the effective concentration of Maslinic acid to be 10-20 μM. 20 μM Maslinic acid significantly suppresses TNF-α production and inhibits IL-1, IL-6, and COX-2 mRNA expression in RAW 264.7 cell. Maslinic acid (at 10 and 20 μM) significantly suppresses the DNA-binding activity of NF-κB p65 in LPS-induced RAW 264.7 cells. Pretreatment with Maslinic acid significantly reduces the LPS-induced phosphorylation of IκB-α[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Paw swelling is alleviated when mice are administered with 200 mg/kg Maslinic acid (MA), significantly suppressing inflammation, compared to the carrageenan induced control group, 4 h after λ-carrageenan injection (0.91±0.51 mm and 1.79±0.4 mm, respectively)[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    472.70

    Formula

    C30H48O4

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@]([C@@]1([H])[C@]2(C[C@@H](O)[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (211.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1155 mL 10.5775 mL 21.1551 mL
    5 mM 0.4231 mL 2.1155 mL 4.2310 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (5.29 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.87%

    References
    Cell Assay
    [1]

    RAW 264.7 cells are seeded in 96-well culture plates at a density of 1×105 cells/mL and after incubation for 24 h, are treated with OPE1 (300 μg/mL or 400 μg/mL), OPE2 (20 μg/mL or 40 μg/mL), or Maslinic acid (10 μM or 20 μM) , as well as with/without LPS at the same time. Cell viability i determined using the WST-1 reagent. Briefly, WST-1 reagent (10 μL) is added to each well and incubated for 1h in a humidified incubator. The absorbance of the samples measured at 450 nm (reference wavelength is 750 nm). Viability is expressed as a percentage of the absorbance measured in LPS-treated cells[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    Five-week-old male Balb/c mice (19-21 g) are housed in a conventional condition and provided with the free access to standard rodent chow and water. Edema is induced by intraplantar injection of 100 μL 1% carrageenan into the hind left paw. Maslinic acid is tested initially at a dose of 200 mg/kg, orally administered 60 min before and after carrageenan injection. Paw thickness is measured using electronic digital calipers, 2, 3, and 4 h following carrageenan treatment. Mice are sacrificed by carbon dioxide inhalation 4 h after carrageenan injection[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1155 mL 10.5775 mL 21.1551 mL 52.8877 mL
    5 mM 0.4231 mL 2.1155 mL 4.2310 mL 10.5775 mL
    10 mM 0.2116 mL 1.0578 mL 2.1155 mL 5.2888 mL
    15 mM 0.1410 mL 0.7052 mL 1.4103 mL 3.5258 mL
    20 mM 0.1058 mL 0.5289 mL 1.0578 mL 2.6444 mL
    25 mM 0.0846 mL 0.4231 mL 0.8462 mL 2.1155 mL
    30 mM 0.0705 mL 0.3526 mL 0.7052 mL 1.7629 mL
    40 mM 0.0529 mL 0.2644 mL 0.5289 mL 1.3222 mL
    50 mM 0.0423 mL 0.2116 mL 0.4231 mL 1.0578 mL
    60 mM 0.0353 mL 0.1763 mL 0.3526 mL 0.8815 mL
    80 mM 0.0264 mL 0.1322 mL 0.2644 mL 0.6611 mL
    100 mM 0.0212 mL 0.1058 mL 0.2116 mL 0.5289 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Maslinic acid
    Cat. No.:
    HY-N0629
    Quantity:
    MCE Japan Authorized Agent: